770671-04-0

Basic information

• Product Name: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-
• Synonyms: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-;1-(3-(4-Methylpiperazin-1-yl)phenyl)guanidine;2-[3-(4-methylpiperazin-1-yl)phenyl]guanidine
• CAS NO: 770671-04-0
• Molecular Formula: C₁₂H₁₉N₅
• Molecular Weight: 233.31276
• Mol File: 770671-04-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-(770671-04-0)
• EPA Substance Registry System: Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]-(770671-04-0)

Safety Data

• Hazardous Substances Data: 770671-04-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Guanidine, N-[3-(4-Methyl-1-piperazinyl)phenyl]is used as a pharmaceutical compound for its potential applications in treating various medical conditions. Its structure and properties suggest it may be effective in addressing central nervous system disorders and cancer, making it a valuable asset for further research and development in medicine.

Upstream product

• 420-04-2 CYANAMID 
• 148546-99-0 3-(4-methylpiperazin-1-yl)aniline 
• 1143571-97-4 (E)-tert-butyl (tert-butoxycarbonylamino)(3-(4-methyl-piperazin-1-yl)-phenylamino)methylenecarbamate 

Downstream Products

• 1142947-79-2 6-amino-5-(2,2-diethoxy-ethyl)-2-[3-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-ol 
• 927653-64-3 4-[1-methyl-3-(4-nitro-phenyl)-1H-pyrazol-4-yl]-N-[3-(4-methyl-piperazin-1-yl)phenyl]-pyrimidin-2-amine 

Relevant articles and documents

Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents

A series of 2,4,5-trisubstituted pyrimidines have been synthesised and characterised, which exhibited potent CDK inhibition and anti-proliferative activities. The structure-activity relationship is analysed and a rational for CDK9 selectivity is discussed

PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS

Provided herein are pyrrolopyrimidine compounds of Formula (I) wherein R1 is a heteroaryl containing at least one S atom, and optionally substituted on a ring carbon by one, two, or three substituents each independently selected from the group consisting of : halo, hydroxyl, nitro, formyl, formamido, cyano, sulfonyl, carboxy, amino, amido, acylamino, carbamoyl, sulphamoyl, alkyl, alkenyl, CF3, ureido, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, carbaldehyde oxime, N -alkylsulphamoyl, N-alkylcarbamoyl, -OR13R11 or -R13R11; R2 is phenyl or pyridinyl, wherein R2 optionally substituted on a ring carbon by one, two, or three substituents each indenpendently selected from the group consisting of : halo, hydroxyl, cyano, nitro, formyl, formamido, carboxy, sulfonyl, amino, amido, -N- alkyl -amino, carbamoyl, sulphamoyl, CF3, ureido, alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkoxycarbonyl, N-alkylsulphamoyl, N-alkylcarbamoyl, -OR11, -OR12R11, or -R12R11; and methods of making and using the same. Such compounds may be used in inflammatory or myeloproliferative disorders. The disclosure also provides for treating cancer.

PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS

Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.